Sharing our knowledge of melanoma on the global stage
15 April 2021
More than 2,000 clinicians and researchers from across the globe will unite online this weekend for the virtual 10th World Congress of Melanoma in conjunction with the 17th EADO Congress.
As leaders in the field of melanoma, many clinicians and researchers from Melanoma Institute Australia (MIA) will be sharing their knowledge as this congress provides an opportunity to educate clinicians on the latest developments in our understanding and treatment of skin cancer.
Here are just a handful of the areas of melanoma research that we will be presenting on:
- Renowned pathologist and MIA’s Co-Medical Director, Prof Richard Scolyer, will discuss how we can predict the likelihood that a patient’s disease will return by examining the molecular profile of their melanoma.
- Medical Oncologist and MIA’s Co-Medical Director Prof Georgina Long AO will be delivering a keynote address discussing if a cure for advanced melanoma is on the horizon. She will review the recent advancements in drug development to treat advanced melanoma, as well as outline the challenges we still face to overcome drug resistance. Prof Long will also highlight the importance of getting our prevention messaging across if we truly want to reach our goal of zero deaths from melanoma.
- Translational researcher Prof Helen Rizos will be reviewing how circulating DNA in the bloodstream can be used as a marker to monitor disease and treatment response in patients with advanced melanoma. This minimally invasive technique can help monitor patients in real-time and is proving to be a valuable new tool to support the clinical care of patients with melanoma.
- Dermatologist Prof Diona Damian will be presenting an overview of nicotinamide (vitamin B3) as a preventative measure to reduce the incidence of non-melanoma skin cancers in high-risk patients.
- Using clinical data alone can help predict which patients will respond well to treatment with immunotherapy. However, when Dr James Wilmott and our team of lab researchers examined biopsies taken from patients before immunotherapy, they found that biopsies showing higher numbers of immune cells touching the melanoma were associated with response and tumour shrinkage. Dr Wilmott will share these findings which will ultimately help select the ideal therapies for patients and will be incorporated into our Personalised Immunotherapy Platform.
Through the combined sharing of knowledge, it is inspiring to see the global commitment to enhancing our understanding of melanoma that will ultimately improve the care of melanoma patients.
Federal government urged
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Lauren O'Brien tells us why she's running for a cause close to her heart
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
“I’m the age Emma was when she passed away. It almost feels
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.